NVAC Influenza Working Group: Preliminary Report

1. NVAC Influenza Working Group: Preliminary Report Charles Helms, M.D., Ph.D. June 1, 2004

2. NVAC Agenda - February, 2004 Influenza 2003-2004: Review and Lessons Learned for the Next Year and the Future • The Current Season • Vaccine Strain Selection Process and Regulatory Issues • Public Perceptions • Perspectives of Influenza Vaccine Manufacturers • Public Sector Roles in Adult and Childhood Influenza Vaccination • CMS • Company perspectives • Health Plans and Insurers • Vaccine Research – NIH • Pandemic Influenza Preparedness

3. The U.S.National Vaccine Plan - 1994 • Develop new and improved vaccines • Ensure the optimal safety and effectiveness of vaccines and immunization • Better educate the public and members of the health professions on the benefits and risks of immunizations • Achieve better use of existing vaccines to prevent disease, disability, and death.

4. NVAC Influenza Vaccine WG Purpose: Evaluate strategies and capabilities to reduce the impact of influenza disease in the US and make recommendations on how to substantially improve prevention and reduce disease burden. A preliminary report will be presented at the June 2004 NVAC meeting.

5. NVAC Influenza WG Subgroups • Influenza Vaccine Research, Development and Production: A. Arvin, Chair • Influenza Vaccine Recommendations and Strategies: J. Klein, Chair • Influenza Vaccine Delivery, Financing, and Demand: F. Guerra, Chair

6. Efforts to Date • WG and SG conference calls: discussion and coordination • Influenza Summit (Atlanta) • Discussions with industry • Preliminary report to NVAC on June 1

7. Next Steps • WG and SG telephone conference calls – June - August • Prepare draft report – September • Present draft at NVAC meeting – October